A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model

Gang Li, Samita Andreansky, Gustavo Helguera, Marjan Sepassi, Nona Janikashvili, Jessica Cantrell, Collin L. LaCasse, Nicolas Larmonier, Manuel L. Penichet, Emmanuel Katsanis

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4+ T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

Original languageEnglish (US)
Pages (from-to)721-729
Number of pages9
JournalMolecular Cancer Therapeutics
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model'. Together they form a unique fingerprint.

  • Cite this